DadFinStart your free week
DadFin › Stocks › Healthcare › XERS

Xeris Biopharma Holdings, Inc. (XERS) stock score

Healthcare · Drug Manufacturers - Specialty & Generic · United States

$10.48 ▲ +2.85% today

84.5
Dad Score, out of 100
good

Xeris Biopharma Holdings, Inc. (XERS) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, listed in the United States. On DadFin's weekly run it scores 84.5 out of 100 on the Dad Score, a good reading that places the business ahead of 84% of the 5,774 US and Canadian stocks DadFin fully scores. Inside Healthcare it ranks #135 of 974. Its strongest axes are valuation, quality and growth; its weakest is conviction.

Scores from the run of Oct 4, 2026. The Dad Score answers one question: how good is this business, measured against its own sector. How it is built →

The eight axes

Valuation
Above average
Quality
Strong
Growth
Strong
Price action
Above average
Risk
Average
Conviction
Below average
Liquidity
Strong
Macro
Average

Each axis is ranked inside the stock's own sector. Subscribers see the percentile and every input behind each bar.

Key numbers

P/E (trailing)0.0×
P/E (forward)23.3×
Dividend yield0.00%
Return on capital10.8%
Operating margin5.6%
Revenue growth (YoY)+43.7%
FCF yield1.6%
Net debt / EBITDA3.44×
Piotroski F-Score8 / 9
52-week change+11.7%
Market cap$1.7B
Next earnings—

What subscribers see on XERS

Start your free weekSubscriber? Open the full research →

Drug Manufacturers - Specialty & Generic peers

StockCompanyDad ScoreBandMarket cap
TAKTakeda Pharmaceutical Company Limi32.9weak$57.1B
TEVATeva Pharmaceutical Industries Lim93.6strong$46.1B
HLNHaleon plc64.5middling$38.7B
ZTSZoetis Inc.61.2middling$28.8B
UTHRUnited Therapeutics Corporation99.8strong$23.2B
VTRSViatris Inc.54.4middling$20.2B
NBIXNeurocrine Biosciences, Inc.98.4strong$14.6B
ELANElanco Animal Health Incorporated84.0good$11.1B

Prices from DadFin's live feed (refreshed about every 15 minutes in the session); scores from the weekly run of Oct 4, 2026. Fundamentals as reported in the latest filings. Research, not investment advice.